Posted inGenetics
GSK, Hengrui Focus on Cancer, Respiratory Diseases, I&I in Up-to-$12.5B Collaboration
GlaxoSmithKline (GSK) will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology, and inflammation…